Intermittent versus Daily Eltrombopag Dosage Protocols for the Treatment of Primary Immune Thrombocytopenia: Real-Life Experience

References

• Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829–2835. doi:10.1182/blood-2017-03-754119.28416506
   PubMed Web of Science ®Google Scholar
• Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620–632. doi:10.1016/j.autrev.2017.04.012.28428120
   PubMed Web of Science ®Google Scholar
• Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2016;3(10):e489–e496. doi:10.1016/S2352-3026(16)30109-0.27658982
   PubMed Web of Science ®Google Scholar
• Matschke J, Müller-Beissenhirtz H, Novotny J, et al. A Randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naïve adult patients with immune thrombocytopenia: EIS 2002 study. Acta Haematol. 2016;136(2):101–107. doi:10.1159/000445420.27189086
   PubMed Web of Science ®Google Scholar
• Cuker A, Cines DB, Neunert CE. Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol. 2016;23(5):479–485. doi:10.1097/MOH.0000000000000270.27380558
   PubMed Web of Science ®Google Scholar
• Palandri F, Polverelli N, Sollazzo D, et al. Have splenectomy rate and main outcomes of ITPchanged after the introduction of new treatments?A monocentric study in the outpatient setting during 35 years. Am J Hematol. 2016;91(4):E267–E272. doi:10.1002/ajh.24310.26799593
   PubMed Web of Science ®Google Scholar
• Mazza P, Minoia C, Melpignano A, et al. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life”retrospective multicenter experience of the ReteEmatologica Pugliese (REP). Ann Hematol. 2016;95(2):239–244. doi:10.1007/s00277-015-2556-z.26596973
   PubMed Web of Science ®Google Scholar
• Elgebaly AS, Ashal GE, Elfil M, Menshawy A. Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: meta-analysis of randomized controlled trials. Clin Appl Thromb Hemost. 2017;23(8):928–937. doi:10.1177/1076029616663849.27572890
   PubMed Web of Science ®Google Scholar
• Brynes RK, Wong RSM, Thein MM, et al. A2-year, longitudinal, prospective study of the effects of eltrombopag on bone marrow inpatients with chronic immune thrombocytopenia. Acta Haematol. 2017;137(2):66–72. doi:10.1159/000452992.28006767
   PubMed Web of Science ®Google Scholar
• Promacta [Package insert]. Research Triangle Park NC. GlaxoSmithKline; 2016 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022291s016,207027s001lbl.pdf. Accessed 710, 2017.
   Google Scholar
• Hayes S, Ouellet D, Zhang J, Wire MB, Gibiansky E. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol. 2011;51(10):1403–1417. doi:10.1177/0091270010383019.21148042
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013;121(14):2596–2606. doi:10.1182/blood-2012-07-442392.23361904
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207. doi:10.1182/blood-2010-08-302984.21325604
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:10.1182/blood-2008-07-162503.19005182
   PubMed Web of Science ®Google Scholar
• Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM. Selective validation of the WHO bleeding scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012;28(1):79–87. doi:10.1185/03007995.2011.644849.22117897
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0; Published 1127, 2017 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 228, 2018.
   Google Scholar
• Gonzalez-Lopez TJ, Pascual C, Alvarez-Roman MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E40–43. doi:10.1002/ajh.23900.25400215
   PubMed Web of Science ®Google Scholar
• Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion. 2013;53(11):2807–2812. doi:10.1111/trf.12139.23451917
   PubMed Web of Science ®Google Scholar
• Wire MB, Bruce J, Gauvin J, et al. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS. Clin Ther. 2012;34(3):699–709. doi:10.1016/j.clinthera.2012.01.011.22336488
   PubMed Web of Science ®Google Scholar
• Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764–776. doi:10.1016/j.clinthera.2009.04.010.19446149
   PubMed Web of Science ®Google Scholar
• Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, non peptide thrombopoietin receptor agonist. Blood. 2007;109(11):4739–4741. doi:10.1182/blood-2006-11-057968.17327409
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018;84(11):2673–2677. doi:10.1111/bcp.13717.30032487
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, Phase 3 study. Lancet. 2011;377(9763):393–402. doi:10.1016/S0140-6736(10)60959-2.20739054
   PubMed Web of Science ®Google Scholar